These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581 [TBL] [Abstract][Full Text] [Related]
3. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973 [TBL] [Abstract][Full Text] [Related]
5. Psychological aspects of active surveillance. van den Bergh RC; Korfage IJ; Bangma CH Curr Opin Urol; 2012 May; 22(3):237-42. PubMed ID: 22357407 [TBL] [Abstract][Full Text] [Related]
6. Economic analysis of active surveillance for localized prostate cancer. Kim S; Dall'Era MA; Evans CP Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666 [TBL] [Abstract][Full Text] [Related]
7. Active surveillance: the Canadian experience. Klotz L Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335 [TBL] [Abstract][Full Text] [Related]
8. The Prostate cancer Research International: Active Surveillance study. Bangma CH; Bul M; Roobol M Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333 [TBL] [Abstract][Full Text] [Related]
10. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. Loeb S; Berglund A; Stattin P J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309 [TBL] [Abstract][Full Text] [Related]
11. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478 [TBL] [Abstract][Full Text] [Related]
12. The economics of active surveillance for prostate cancer. Dall'Era MA Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496 [TBL] [Abstract][Full Text] [Related]
13. Further support for active surveillance in the management of low-volume, low-grade prostate cancer. Albertsen P Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512 [No Abstract] [Full Text] [Related]
14. Disease-specific and patient-reported outcomes under active surveillance. Venderbos LD; Bangma CH; Korfage IJ Curr Opin Urol; 2015 May; 25(3):267-71. PubMed ID: 25730326 [TBL] [Abstract][Full Text] [Related]
15. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. Holmström B; Holmberg E; Egevad L; Adolfsson J; Johansson JE; Hugosson J; Stattin P; J Urol; 2010 Oct; 184(4):1322-7. PubMed ID: 20723940 [TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. Holmberg L; Bill-Axelson A; Helgesen F; Salo JO; Folmerz P; Häggman M; Andersson SO; Spångberg A; Busch C; Nordling S; Palmgren J; Adami HO; Johansson JE; Norlén BJ; N Engl J Med; 2002 Sep; 347(11):781-9. PubMed ID: 12226148 [TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. Aizer AA; Paly JJ; Zietman AL; Nguyen PL; Beard CJ; Rao SK; Kaplan ID; Niemierko A; Hirsch MS; Wu CL; Olumi AF; Michaelson MD; D'Amico AV; Efstathiou JA J Clin Oncol; 2012 Sep; 30(25):3071-6. PubMed ID: 22851571 [TBL] [Abstract][Full Text] [Related]
18. Sexual function with localized prostate cancer: active surveillance vs radical therapy. van den Bergh RC; Korfage IJ; Roobol MJ; Bangma CH; de Koning HJ; Steyerberg EW; Essink-Bot ML BJU Int; 2012 Oct; 110(7):1032-9. PubMed ID: 22260273 [TBL] [Abstract][Full Text] [Related]
19. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782 [TBL] [Abstract][Full Text] [Related]
20. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Chou R; Croswell JM; Dana T; Bougatsos C; Blazina I; Fu R; Gleitsmann K; Koenig HC; Lam C; Maltz A; Rugge JB; Lin K Ann Intern Med; 2011 Dec; 155(11):762-71. PubMed ID: 21984740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]